Interview with Lars Lannfelt, founder of Bioarctic

Last year, we were so happy to learn the result of the Eisai US/BioArctic phase 3 clinical trial where treatment with the antibody Lecanemab was shown to significantly delay the progression of Alzheimer’s disease. Happy, and also very proud, as the original murine monoclonal antibody, now used in a humanized form, was once developed as part of a collaboration between BioArctic, Uppsala University and Mabtech.
 
We invited Lars Lannfelt, professor and co-founder of Bioarctic, to our headquarters in Nacka Strand, to tell the story behind the antibody's development, function, and its potential clinical applications. Although that presentation was for our ears only, we managed to also film a short interview with Lars, that we want to share with you here and now. 

Enjoy!